NRX Pharmaceuticals Inc (NRXP) - Net Assets
Based on the latest financial reports, NRX Pharmaceuticals Inc (NRXP) has net assets worth $-25.75 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($15.00 Million) and total liabilities ($40.75 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check NRX Pharmaceuticals Inc asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-25.75 Million |
| % of Total Assets | -171.75% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 106.65 |
NRX Pharmaceuticals Inc - Net Assets Trend (2017–2024)
This chart illustrates how NRX Pharmaceuticals Inc's net assets have evolved over time, based on quarterly financial data. Also explore how large is NRX Pharmaceuticals Inc's balance sheet for the complete picture of this company's asset base.
Annual Net Assets for NRX Pharmaceuticals Inc (2017–2024)
The table below shows the annual net assets of NRX Pharmaceuticals Inc from 2017 to 2024. For live valuation and market cap data, see NRXP company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $-23.22 Million | -97.93% |
| 2023-12-31 | $-11.73 Million | -258.36% |
| 2022-12-31 | $7.41 Million | -64.39% |
| 2021-12-31 | $20.81 Million | +147.53% |
| 2020-12-31 | $-43.77 Million | -248.37% |
| 2019-12-31 | $29.50 Million | -57.58% |
| 2018-12-31 | $69.54 Million | +0.10% |
| 2017-12-31 | $69.47 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to NRX Pharmaceuticals Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 27816796700.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $15.00K | % |
| Other Components | $255.03 Million | % |
| Total Equity | $-23.22 Million | 100.00% |
NRX Pharmaceuticals Inc Competitors by Market Cap
The table below lists competitors of NRX Pharmaceuticals Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Adveritas Ltd
AU:AV1
|
$58.91 Million |
|
Awale Resources Ltd
V:ARIC
|
$58.97 Million |
|
Iskandar Waterfront City Bhd
KLSE:1589
|
$58.97 Million |
|
RBZ Jewellers Limited
NSE:RBZJEWEL
|
$58.97 Million |
|
Welspun Investments and Commercials Limited
NSE:WELINV
|
$58.91 Million |
|
SK Innovation Co Ltd Pref
KO:096775
|
$58.91 Million |
|
APEX International Financial Engineering Res & Tech Co Ltd
TWO:5210
|
$58.90 Million |
|
Y-Optics Manufacture Co. Ltd
KQ:066430
|
$58.89 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in NRX Pharmaceuticals Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -11,733,000 to -23,223,000, a change of -11,490,000.
- Net loss of 25,126,000 reduced equity.
- New share issuances of 5,911,000 increased equity.
- Other comprehensive income increased equity by 3,000.
- Other factors increased equity by 7,722,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-25.13 Million | -108.19% |
| Share Issuances | $5.91 Million | +25.45% |
| Other Comprehensive Income | $3.00K | +0.01% |
| Other Changes | $7.72 Million | +33.25% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares NRX Pharmaceuticals Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | $76.89 | $3.09 | x |
| 2018-12-31 | $77.91 | $3.09 | x |
| 2019-12-31 | $57.98 | $3.09 | x |
| 2020-12-31 | $-80.08 | $3.09 | x |
| 2021-12-31 | $0.44 | $3.09 | x |
| 2022-12-31 | $0.11 | $3.09 | x |
| 2023-12-31 | $-1.55 | $3.09 | x |
| 2024-12-31 | $-2.21 | $3.09 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently NRX Pharmaceuticals Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-122.82%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | -0.15% | 0.00% | 0.00x | 1.00x | $-7.05 Million |
| 2018 | 0.10% | 0.00% | 0.00x | 1.02x | $-6.89 Million |
| 2019 | 1.38% | 0.00% | 0.00x | 1.09x | $-2.54 Million |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-47.40 Million |
| 2021 | -447.29% | 0.00% | 0.00x | 1.57x | $-95.14 Million |
| 2022 | -536.56% | 0.00% | 0.00x | 3.48x | $-40.49 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-28.98 Million |
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | $-22.80 Million |
Industry Comparison
This section compares NRX Pharmaceuticals Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| NRX Pharmaceuticals Inc (NRXP) | $-25.75 Million | -0.15% | N/A | $58.91 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About NRX Pharmaceuticals Inc
NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder, and chronic pain. Its lead drug candidates include NRX-101, an oral, fixed dosed combination of D-cycloserine and lurasidone for suicidal treatment-resistant bipolar depression in p… Read more